-
Product Insights
NewNet Present Value Model: Turnstone Biologics Corp’s TIDAL-01
Empower your strategies with our Net Present Value Model: Turnstone Biologics Corp's TIDAL-01 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Passage Bio Inc’s PBGM-01
Empower your strategies with our Net Present Value Model: Passage Bio Inc's PBGM-01 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SJ-01 in Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SJ-01 in Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SJ-01 in Anemia Drug Details: SJ-01 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CBAC-01 in Stroke
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CBAC-01 in Stroke report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CBAC-01 in Stroke Drug Details: CordSTEM-ST is under development for the treatment...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – AMO-01 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMO-01 in Epilepsy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMO-01 in Epilepsy Drug Details: AMO-01 (TLN-4601) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LTI-01 in Empyema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LTI-01 in Empyema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LTI-01 in Empyema Drug Details: LTI-01 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CEB-01 in Leiomyosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CEB-01 in Leiomyosarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CEB-01 in Leiomyosarcoma Drug Details: CEB-01 is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – CEB-01 in Liposarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CEB-01 in Liposarcoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CEB-01 in Liposarcoma Drug Details: CEB-01 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TDI-01 in Pneumoconiosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TDI-01 in Pneumoconiosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TDI-01 in Pneumoconiosis Drug Details: TDI-01 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-01 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-01 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-01 in Pancreatic Cancer Drug Details: TG-01 is under development for the...